High Throughput Flow Assay Trends 2015
|出版日期||內容資訊||英文 55 Pages
This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on high throughput flow cytometry (HT flow) screening carried out in December 2014.
The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces.
The questionnaire was compiled to meet the needs, requirements and interests of the HT flow vendor community. The objectives were to document the current implementation and use of HT flow assays in screening, and to understand future user requirements.
Equal emphasis was given to soliciting opinion from the antibody/biologics, small molecule and immunoassay screening segments worldwide.
The survey looked at the following aspects of HT flow screening, as practiced today (late 2014) and in a few cases as predicted for the future (2017): why respondents have enabled or why they are interested in HT flow; how respondents have achieved HT flow analysis to date and typical throughput realised with current instrument approach; will implementing HT flow mainly displace or complement existing screening technologies; key diseases/therapeutic areas targeted with HT flow screening; target classes most interested in applying HT flow assays; broad applications areas most using or most considering using HT flow assays; applications areas most suited to an HT flow approach; main benefits of HT flow versus other techniques; plate processing time considered adequate for HT flow needs; preferred sample presentation/handling format for HT flow and what is the target sample (aspirate) volume; number of parameters of information wanted to multiplex simultaneously; samples types wanted to analyse with HT flow; where cell markers of interest in HT flow screens are located; main cell labelling technique/source; type of endpoints of most interest in HT flow screens; intention to carry out any front end processing or sample preparation prior to HT flow; number of different primary screens and number of wells to be tested per HT flow screen; estimated cost per sample (microplate well) analysed using HT flow assays; vendor that first comes to mind when thinking of flow cytometry in general and HT flow specifically; plans to purchase any instrumentation to enable HT flow assays; capex budget for HT flow detection instruments; reagents and consumables budget for HT flow assays; how respondents have deployed HT flow instrumentation into their screening environment/core facility; biggest limitations (obstacles) in using HT flow assays today; ranking of possible limitations of HT flow; biggest hurdles in software and data analysis for HT flow; areas where respondents have deployed or are considering deploying HT flow assays; level of agreement with statements about the status of HT flow assays; awareness of alternative technologies for HT flow; and any unmet needs in HT flow screening today.
The main questionnaire consisted of 28 multi-choice questions and 3 open-ended questions. In addition, there were 6 questions related solely to administration/survey demographics.
The survey collected 80 validated responses, of these 61% provided comprehensive input.
Survey responses were geographically split: 57% North America; 31% Europe; 5% Asia (excluding Japan & China); 4% Japan and 3% China.
Survey respondents were drawn from persons or groups undertaking HT flow screening or those contemplating future investigation in the area.
Respondents represented 34 University/Res. Inst./Govn't Lab/Not-For-Profit; 17 Biotech Company; 9 Biopharma; 7 Large Pharma; 5 Medium-Small Pharma; 3 Contract Research Organisation; 2 Academic Screening Center; 2 Other; and 1 Medical School/Hospital/Clinic.
Most survey respondents had a senior job role or position which was in descending order: 21 research scientists; 13 senior scientists/researchers; 12 principal investigators; 9 other roles; 6 lab managers; 5 professors/assistant professors; 4 post-docs; 4 department heads; 3 graduate/PhD students; 2 directors; and 1 section/group leader.
Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalyzed after sub-division into the following 5 survey groups: 1) Antibody/Biologics Screening; 2) Small Molecule Screening; 3) Immunoassay Screening; 4) Using; and 5) Not Yet Using.
Feedback on why respondents have enabled or why they are interested in HT flow was documented.
The majority of respondents were using HT flow assays in screening today, the remainder aspire to or intend to implement in the near future.
HT flow analysis has been most achieved to date by using a flow cytometer with sample acquisition enabled direct from microplate wells.
The median throughput realized to date by current approaches to HT flow was 500-1K samples/day.
The majority of respondents believe implementing HT flow will complement existing technologies.
The majority of respondents were targeting HT flow assays within the oncology/cancer area.
Respondents rated they were most interested in applying HT flow assays to membrane receptors.
Respondents use or planned use of HT flow assays was split relatively evenly between antibody/biologics screening, small molecule/compound library screening and immunoassay screening.
Antibody screening was selected the key application areas most suited to an HT flow approach.
Ability to analyse multiple cell populations within each microplate well was ranked the greatest benefit (advantage) of HT flow versus other techniques.
The median requirements for flow sampling and analysis were: 96-well plate for sample presentation/handling format; 10 min total plate processing time; 5-10μL sample (aspirate) volume; and 5-7 parameters of information acquired (multiplexed) simultaneously from the same sample.
The samples types most want to analyze by HT flow assays were cultured suspension cell lines for whole population studies and human blood samples for sub-population studies.
Cell markers of interest regularly targeted by HT flow were mainly located on the cell surface.
Commercial antibodies were rated the main source used for HT flow assays.
The type of end points used in HT flow assays typically included those that reported both cell function(s) and cell health.
Most respondents undertake sample prep to improve the detection of all cells prior to HT flow assay.
A median of 2 primary (HTS) screens each with 1k to 5k wells were run by HT flow today (2014).
The median cost paid per sample analysed using HT flow assays today (2014) was $0.25-$0.5/well.
The vendor that first comes to mind for flow cytometry in general was BD Biosciences.
The vendor that first comes to mind for HT flow specifically was Intellicyt.
Only a minority of respondents have purchased instruments enabling HT flow screening in 2014.
The median purchasing probability over the next few years (up to 2017) was possible (26-50% probability).
The preferred vendors for new HT flow instrumentation purchasing were Intellicyt and BD Biosciences.
The median annual capex budget for HT flow detection instruments was $75K-$100K.
The global market for HT flow detection instruments was estimated to be $45M in 2014.
The median annual budget for reagents and consumables for HT flow assays was $25K-$50K.
The global market for HT flow reagents and consumables was estimated to be $47M in 2014.
The main deployment HT flow instrumentation into a screening environment/core facility was as part of a semi-automated setup (e.g. with some additional peripheral automation and liquid handling).
Feedback on the biggest limitations in using HT flow assays were documented.
Investment in additional expensive instrumentation was rated as the main limitation of HT flow assays.
Interpreting complex multi-parametric data was ranked the biggest hurdle in software and data analysis for HT flow assays.
The main area where HT flow assays have been deployed or deployment is planned was basic research.
The level of agreement with statements about the status of HT flow assays was most positive (i.e. of greatest agreement) with ‘HT flow is the ideal high content platform for phenotypic screening'; and most negative (i.e. of greatest disagreement) with ‘HT flow is nothing more than a prescreen for more sophisticated imaging-based analyses'.
The majority were not aware of any alternative technologies for HT flow assays that is or sounds more useful or more appealing than Intellicyt's HyperCyt autosampler or iQue Screener system (i.e. uses "air gap delimited" aspiration and sample feed).
Some feedback on any unmet needs in HT flow assays today were documented.
The full report provides the data, details of the breakdown of the responses to each question, its segmentation and estimates for the future (2017). It also highlights some interesting differences between the survey groups.
For the purpose of this report HT flow assays were defined as those that utilize automated sampling methods to transfer from a microplate assay components suspended in solution (including cells, beads, yeast and bacteria) to the flow cytometer detector in a continuous stream. Typically multiple parameters are simultaneously multiplexed from the same sample.